Avtozma (tocilizumab-aazg)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTER (if different than prescriber):	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** **IF RENEWAL:** DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company

Avtozma (tocilizumab-aazg)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ **YES** (if yes, complete below) ☐ **NO**		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ Moderate to severely active rheumatoid arthritis (RA) ☐ Polyarticular juvenile idiopathic arthritis (pJIA) ☐ Systemic juvenile Idiopathic arthritis (sJIA) ☐ Giant Cell Arteritis ☐ Other diagnosis: _____ ICD-10 Code(s):	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is patient going to be using drug in combination with a clinical trial? ☐ Yes ☐ No

Initial Request:

Is the drug being prescribed by a rheumatologist? □ Yes □ No

Is the patient on concurrent treatment with another biologic or other immunomodulatory agent (i.e., Rituxan, Orencia, Remicade, Humira, Kineret, Enbrel, Simponi, Cimzia, etc.)? □ Yes □ No Please submit documentation.

Has the patient tried and had an inadequate response to a three month trial of the biosimilar for Humira- adalimumab-aacf? □ Yes □ No Please submit documentation.

Does patient have an absolute contraindication to the biosimilar adalimumab-aacf? □ Yes □ No Please submit documentation.

Has the patient tried and had an inadequate response to a three month trial of the biosimilar for Actemra – Tyenne(tocilizumab-aazg)? □ Yes □ No Please submit documentation.

Does patient have an absolute contraindication to the biosimilar Tyenne(tocilizumab-aazg)? □ Yes □ No Please submit documentation.

For a moderate to severe active rheumatoid arthritis (RA), also answer the following:
Has the patient had a trial of methotrexate or another oral non-biologic disease modifying anti-rheumatic agent (DMARD) such as Imuran, Ridaura, Plaquenil, Sulfasalazine or Arava? □ Yes □ No Please submit documentation.

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company

Avtozma (tocilizumab-aazg)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Is the patient unable to take the prerequisite non-biologic DMARD due to their chronic liver disease (such as chronic hepatitis, chronic alcohol abuse/alcoholism, fatty liver, nonalcoholic steatohepatitis/NASH, or elevated liver enzymes? □ Yes □ No Please submit documentation.

For Polyarticular juvenile idiopathic arthritis(pJIA) or systemic juvenile idiopathic arthritis(sJIA, also answer the following:
Does the patient have active polyarticular? □ Yes □ No
Does the patient have active systemic JIA? □ Yes □ No

Has the patient had an inadequate response to, intolerance to, or contraindication to one or more non-biologic DMARDs? □ Yes □ No Please submit documentation.

Is the patient age 2-17 years with axial spondyloarthropathy? □ Yes □ No

For Giant Cell Arteritis:
Is the patient 50 years of age or older? □ Yes □ No

Is the patient currently on oral prednisone at a daily dose of between 20mg and 60mg per day? □ Yes □ No Please submit documentation.

For Renewal Requests:
Is patient continuing to demonstrate a positive clinial response?

Is prescriber a rheumatologist or in consult with a rheumatologist?

Is the patient on concurrent treatment with another biologic or other immunomodulatory agent (i.e., Rituxan, Orencia, Remicade, Humira, Kineret, Enbrel, Simponi, Cimzia, etc.)? □ Yes □ No Please submit documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company
Prime Therapeutics Management – Commercial Clients. Revision Date: 7.1.26
CAT009

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company
Prime Therapeutics Management – Commercial Clients. Revision Date: 7.1.26
CAT009